CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 7 enrolled
Drug / intervention
Pembrolizumabdrug
Likely dose
Pembrolizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04317066
NCT04317066Phase 1Completed
CompareCT.gov

A Phase 1 Clinical Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (KEYNOTE-A33)

Merck Sharp & Dohme LLC·interventional·Posted Mar 20, 2020·Updated Apr 6, 2025

In Brief

A Phase 1 clinical trial evaluating Pembrolizumab for Lymphoma, B-Cell. Completed, enrolled 7 participants across 9 sites.

Detailed Summary

The purpose of this study is to evaluate the objective response, safety, and tolerability of pembrolizumab in Japanese participants who have refractory primary mediastinal large B-cell lymphoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, B-Cell
CountriesJapan
Collaborators--

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedMar 20, 2020
Enrollment StartJun 26, 2020
Primary CompletionApr 11, 2024
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 6.3 years ago

Interventions

Pembrolizumabdrug

Pembrolizumab 200 mg by intravenous (IV) infusion, given on day 1 of each 3-week cycle.